The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19

Q: What does this research mean for the field?

Treatment of moderate to severe COVID-19 patients with natural killer (NK) cells from COVID-19 convalescent donors is feasible and safe. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Clara Hernández-Blanco; Karima Al‐Akioui‐Sanz; Lara Herrera; Cristina Aguirre-Portolés; Daniel Lozano‐Ojalvo; Leticia Pérez‐Rodríguez; Jordi Cano-Ochando; Pilar Guerra‐García; Alejandro Martín‐Quirós; José L. Vicário; Silvia J. Santos; Miguel Ángel Pérez-Vaquero; Miguel Ángel Vesga; Alberto M. Borobia; Antonio J. Carcas; A. Balas; Miguel Ángel Moreno; Rebeca Pérez de Diego; Mercedes Gasior Kabat; Bernat Soria; Cristina Eguizábal; Antonio Pérez‐Martínez

doi:10.1016/j.isci.2024.111698

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

/kg of NK cells. All participants' clinical status and inflammation markers were monitored. No serious adverse events were reported after infusion. Exploratory outcomes included the donor chimerism, NK-cell immunophenotype evolution, and immune lymphocyte reconstitution. This study provides preliminary evidence supporting the idea that treatment of COVID-19 patients with moderate/severe symptoms using NK from COVID-19 convalescent donors is feasible and safe.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hernández-Blanco et al. (2024) studied this question.

synapsesocial.com/papers/6a22e06d76b749c0f266630f https://doi.org/10.1016/j.isci.2024.111698

View Full Paper

Ask AI

Bookmark

Share

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading